Neuralink Corp.: Business Overview, Financials & Competitive Analysis
Neuralink Corp. scores 8/10 on the AskCyborg Cyborg Score (Strong). Neuralink is positioned to become a transformative medical-technology platform if it successfully scales production and navigates regulatory/ethical challenges while expanding its three-product commercial roadmap. Two FDA Breakthrough designations and international regulatory approvals establish Neuralink at the forefront of transformative medical technology. The company plans high-volume production and almost entirely automated.
What is Neuralink Corp.'s industry? Neuralink Corp. (neuralink.com) operates in Neurostimulation Devices. AskCyborg classifies Neuralink Corp. under Neurostimulation Devices in its company registry.
Neuralink is an American neurotechnology company developing implantable brain-computer interfaces (BCIs). The company has achieved clinical validation with paralyzed patients controlling cursors, playing video games, ...
Cyborg Score thesis
Neuralink is positioned to become a transformative medical-technology platform if it successfully scales production and navigates...
Read the full analyst-debate transcript →Get the Latest Neuralink Corp. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeNeuralink Corp. Overview
Pro stress-test →Neuralink is an American neurotechnology company developing implantable brain-computer interfaces (BCIs). The company has achieved clinical validation with paralyzed patients controlling cursors, playing video games, operating robotic arms, and communicating through thought alone. Founded in 2016 by Elon Musk, the company has begun human trials and raised $650 million in Series C funding to expand clinical testing and manufacturing.
Strategic Profile
Pro stress-test →Neuralink enters 2026 as the clear leader in brain-computer interface development, having achieved clinical validation, international expansion, and substantial capital raising. The company's main opportunity lies in rapidly increasing BCI power through its 'Moore's Law for neurons' concept, with plans to increase electrode density from 1,024 to 3K by 2026, 10K by 2027, and over 25K by 2028 to enable advanced applications like real-time speech decoding. Neuralink projects $1 billion in annual revenue by 2031 through three product lines: Telepathy, Blindsight, and Deep, with targets of 2,000 Telepathy procedures by 2029 and 10,000 Blindsight procedures by 2030.
Competitive Landscape
Pro stress-test →Neuralink's biggest competitor, Synchron, has implanted its BCI successfully in around 10 patients. Beijing Xinzhida Neurotechnology, supported by Chinese government backing, has successfully implanted devices in three patients in March 2025 and plans trials with 50 patients in 2026, aggressively scaling to surpass Western BCI developers. Precision Neuroscience, founded by Neuralink co-founder Benjamin Rapoport, uses less-invasive surface electrodes to address safety concerns.
Industry Context
Neuralink Corp. operates in Neurostimulation Devices.
Key facts
Founded: 2016 · Headquarters: Fremont, US · Employees: 635 · Revenue: N/A